Opinion|Videos|January 12, 2026
Emerging Therapies in Schizophrenia
Panelists discuss how emerging therapies targeting new pathways may revolutionize schizophrenia management.
Advertisement
Episodes in this series
Panelists discuss how innovative treatments—including glutamatergic modulators, muscarinic agonists, and digital interventions—represent the next frontier of schizophrenia care.
Panelists discuss how these new agents aim to address cognitive and negative symptoms often resistant to traditional therapy, filling critical gaps in patient outcomes.
Panelists discuss how combining emerging pharmacologic innovations with technology-driven support could transform disease management over the next decade.
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
FDA Approves Pirtobrutinib for Untreated CLL/SLL Without 17p Deletion
3
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
4
Who Recommends COVID-19 Vaccines Without ACIP?
5